Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

ROCHESTER, N.Y., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
September 25, 2018 08:30 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference

ROCHESTER, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
August 09, 2018 09:08 ET | Source: Vaccinex, Inc.

Vaccinex Announces Pricing of Initial Public Offering

ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
January 30, 2018 11:14 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease

ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
January 08, 2018 13:10 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology

ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...
October 26, 2017 10:23 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)

ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
April 24, 2017 10:28 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)

- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...
October 06, 2016 09:45 ET | Source: Vaccinex, Inc.

Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer

ROCHESTER, N.Y., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to evaluate VX15/2503, an...
September 09, 2016 09:45 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial

ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
August 23, 2016 10:15 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease

ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...